Mankind Pharma Ltd, the fourth-largest pharmaceutical company in India, is gearing up to raise over ₹9,000 crore through a combination of non-convertible debentures (NCDs) and short-term commercial paper. This move is part of the company’s strategy to support its ₹13,630 crore acquisition of Bharat Serums and Vaccines Ltd (BSV), a deal first announced in late July.
The company anticipates an…
